ORIGINAL RESEARCH—ED PHARMACOTHERAPY
The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA
Article first published online: 12 AUG 2013
© 2013 International Society for Sexual Medicine
The Journal of Sexual Medicine
Volume 10, Issue 11, pages 2790–2797, November 2013
How to Cite
Wang, Z., Zhu, D., Yang, X., Li, J., Jiang, X., Tian, G., Terrett, N. K., Jin, J., Wu, H., He, Q., Yang, B. and Shen, J. (2013), The Selectivity and Potency of the New PDE5 Inhibitor TPN729MA. Journal of Sexual Medicine, 10: 2790–2797. doi: 10.1111/jsm.12285
- Issue published online: 4 NOV 2013
- Article first published online: 12 AUG 2013
- National Science and Technology Major Project. Grant Numbers: 2009ZX09102-056, 2012ZX09301001-001
- National High Technology Research and Development Program of China. Grant Numbers: 2007AA02Z145, 2012AA020302
- Key Project of Shanghai Science and Technology Commission for Fundamental Research and Development. Grant Number: 12431901702
- Innovation Fund for Technology Based Firms of Shanghai City. Grant Number: 1002H117400
- Erectile Dysfunction;
- Phosphodiesterase 5 Inhibitors;
- Cyclic Guanosine Monophosphate;Selectivity and Potency
TPN729MA is a newly developed phosphodiesterase type 5 inhibitor (PDE5i) for the treatment of erectile dysfunction, which offers potential for greater selectivity and longer duration of action than PDE5i in current clinical use.
We investigated the in vitro inhibitory potency and selectivity of TPN729MA on PDE isozymes, and its efficacy in animal models.
The inhibition of 11 human recombinant PDEs by TPN729MA, sildenafil, and tadalafil were determined using radioimmunoassay. The effect of TPN729MA and sildenafil on intracavernous pressure (ICP), blood pressure (BP), and ICP/BP ratio were determined in a rat model of erection induced by electric stimulation and in a dog model of erection induced by sodium nitroprusside injection.
Main Outcome Measures
The main outcome measures were IC50 of TPN729MA, sildenafil, and tadalafil for PDE1-PDE11; maximum ICP; BP and ICP/BP ratio.
The IC50 of TPN729MA, sildenafil, and tadalafil for PDE5 was 2.28, 5.22, and 2.35 nM, respectively. TPN729MA showed 248, 366, 20, and 2671-fold selectivity against PDE1, PDE4, PDE6, and PDE11, respectively. TPN729MA showed excellent selectivity against PDE2, 3, 7, 8, 9, and 10 (>10,000-fold). In the rat model of erection, TPN729MA (5.0 and 2.5 mg/kg), but not sildenafil, significantly increased the maximum ICP compared with vehicle. Significantly increased ICP/BP was observed in the TPN729MA (5.0 mg/kg) group at all time points, in the TPN729MA (2.5 mg/kg) group at 75, 90, 105, and 120 minutes time points, and in sildenafil group at 75 and 90 minutes time points compared with vehicle. In the dog model of erection, TPN729MA and sildenafil significantly increased ICP and ICP/BP but showed no significant effect on BP compared with vehicle.
TPN729MA is a potent PDE5i with a balanced selectivity profile. TPN729MA shows excellent in vitro and in vivo potency, and a longer effect on erectile function than sildenafil in animal model. Wang Z, Zhu D, Yang X, Li J, Jiang X, Tian G, Terrett NK, Jin J, Wu H, He Q, Yang B, and Shen J. The selectivity and potency of the new PDE5 Inhibitor TPN729MA. J Sex Med 2013;10:2790–2797.